Balancing the Pace of Analytical Technological Advancement with Evolving Regulatory Frameworks
The pharmaceutical industry has experienced considerable transformation over the past decade, characterized by a notable shift towards biologics and a revived focus on peptide and oligonucleotide drug modalities. It has also witnessed significant changes in the regulatory landscape, particularly with the recent implementation of Analytical Quality by Design concepts. The full ramifications and impacts of these developments on pharmaceutical quality control are yet to be completely ascertained. In this panel discussion, we will explore how this evolving environment, alongside pressing sustainability concerns, drives and fosters innovation in advanced pharmaceutical analytics. We will deliberate on strategies and analytical solutions designed to address the future of quality control, encompassing both the principles of quality and sustainability.
